Pages that link to "Q35944699"

The following pages link to Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma (Q35944699):

Displaying 22 items.

• CRNDE: A Long Non-Coding RNA Involved in CanceR, Neurobiology, and DEvelopment (Q28391523) ‎ (← links)
• Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells (Q28487347) ‎ (← links)
• In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes (Q33590961) ‎ (← links)
• Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. (Q33634389) ‎ (← links)
• A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy (Q33757020) ‎ (← links)
• SAMSN1 is a tumor suppressor gene in multiple myeloma (Q34347229) ‎ (← links)
• RECQ helicases are deregulated in hematological malignancies in association with a prognostic value (Q36577713) ‎ (← links)
• Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells (Q36782357) ‎ (← links)
• Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. (Q37083880) ‎ (← links)
• Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma (Q37144899) ‎ (← links)
• The genetic architecture of multiple myeloma. (Q38001913) ‎ (← links)
• Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation. (Q38394274) ‎ (← links)
• Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy (Q38617375) ‎ (← links)
• In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. (Q38910971) ‎ (← links)
• Gene expression-based risk score in diffuse large B-cell lymphoma (Q42153541) ‎ (← links)
• Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients (Q42409849) ‎ (← links)
• CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma (Q47125786) ‎ (← links)
• IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. (Q50861647) ‎ (← links)
• DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. (Q52676395) ‎ (← links)
• An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. (Q55106924) ‎ (← links)
• Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact (Q92126698) ‎ (← links)
• BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma (Q92996161) ‎ (← links)